Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1600 participants
OBSERVATIONAL
2009-10-31
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed Informed consent
* Laboratory analysis (lipidic profile and glycemia) performed in the last year
Exclusion Criteria
* Patients enrolled in clinical studies which the aim is to evaluate the efficacy and/or tolerability of anti-hypertensive and/or lipid lowering drugs
* Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mario Mangrella
Role: STUDY_CHAIR
AstraZeneca S.p.A., R&D
Raffaele Sabia
Role: STUDY_DIRECTOR
AstraZeneca S.p.A., R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research
Foligno, , Italy
Research Site
Perugia, , Italy
Research Site
Terni, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CIT-DUM-2008/1
Identifier Type: -
Identifier Source: org_study_id